The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings.
This blog post is a collection of HIV/HCV highlights that were presented at CROI 2017. Please scroll down and click on the subjects that interest you.
More Interesting CROI 2017 Abstracts about HIV/HCV Coinfection
- INF-Free Therapy is Effective and Safe for HCV Recurrence in LT HCV/HIV Coinfection (Abstract Number 540) by Christian Manzardo, et al.
- HCC Development in HCV Patients after DAA: The Experience of the Scolta Project (Abstract Number 542LB) by Barbara Menzagh, et al.
- Direct-Acting Antivirals Improve Access to Care and Cure for Patients with HIV-HCV (Abstract Number 552) by Lauren F. Collins, et al.
- HCV Treatment in People who Inject Drugs Colocated within Needle and Syringe Program (Abstract Number 554) by Benjamin Eckhardt, et al.
- Ninety-six % SVR Rated Using Imported Generic DAAs for Patients with Hepatitis C (Abstract Number 569) by Andrew Hill, et al.
- Viral Kinetics Predicts Response to All-Oral Therapy Against HCV Genotype 3 Infection (Abstract Number 570) by Juan A. Pineda, et al.
More information about The Conference on Retroviruses and Opportunistic Infections (CROI), or these and other studies can be found in our blog post CROI 2017 Hep C Highlights Part I or on the conference’s website.